Storm over delisted medicine prices

Debate is heating up after revelations that the OTC cost of Panadol Osteo was not comparable with its concessional card price, as had been promised prior to its 1 January PBS delisting.

With public concern growing over the increased cost of the medicine there are now claims that the government may have been incorrect in calculating its cost post-delisting.

Federal Minister for Health Sussan Ley has asked the Department of Health to “urgently alert” the ACCC over a 50% price increase by Panadol Osteo manufacturer GSK, which she says aims to mislead consumers and

Latest

Trending